GlassScriptPhysician profile
Istvan Tomaschek
NPI 1487188819
$41,057.92
in general payments reported to CMS, 2019-2025
29 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $485 · 2023: $2,909 · 2024: $3,730 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $10K · Honoraria: $7,200 · Consulting Fee: $1,525 · Travel and Lodging: $338 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,776.25 |
| Food and Beverage | $10,464.45 |
| Honoraria | $7,200.00 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $338.24 |
| Education | $122.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,967.42 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Axsome Therapeutics, INC. | $7,729.13 | 2025 | Symbravo |
| Pfizer INC. | $6,984.77 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,186.48 | 2022-2025 | Ajovy, Austedo Xr |
| Lundbeck LLC | $924.40 | 2023-2025 | Vyepti |
| Lilly USA, LLC | $816.72 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Tonix Medicines, INC. | $732.18 | 2024-2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $463.08 | 2022-2023 | Trudhesa |
| Amgen INC. | $430.37 | 2022-2024 | Aimovig |
| Ucb, INC. | $361.93 | 2023-2025 | Nayzilam, Briviact |
| Currax Pharmaceuticals LLC | $335.88 | 2023-2025 | Onzetra Xsail, Contrave |
| Scilex Pharmaceuticals INC. | $192.29 | 2023-2025 | Elyxyb |
| Eisai INC. | $153.86 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $121.82 | 2021 | |
| Averitas Pharma INC. | $97.52 | 2024-2025 | Qutenza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $92.27 | 2023-2025 | Wegovy |
| Upsher-Smith Laboratories LLC | $76.87 | 2022-2023 | |
| Impel Pharmaceuticals LLC | $73.63 | 2024 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $62.09 | 2023 | Eprontia, Gliadel |
| Merck Sharp & Dohme LLC | $57.92 | 2023-2024 | Welireg |
| Biohaven Pharmaceutical Holding Company LTD. | $34.84 | 2022 | |
| Csl Behring | $27.72 | 2025 | Hizentra |
| Novocure INC. | $27.45 | 2022-2023 | Optune |
| Genzyme Corporation | $25.05 | 2021 | |
| Corium, LLC | $24.55 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $21.20 | 2024 | Avastin |
| Collegium Pharmaceutical, INC. | $18.85 | 2023 | Belbuca |
| Ibsa Pharma INC. | $17.63 | 2025 | Tirosint, Licart, Flector |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$417,134.46 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Istvan Tomaschek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.